SOBRsafe Inc. (NASDAQ: SOBR), a provider of next-generation alcohol detection technology, announced it has entered into definitive agreements for the immediate exercise of certain outstanding warrants at a reduced exercise price of $1.05 per share. The transaction is expected to generate gross proceeds of approximately $3.1 million before deducting placement agent fees and other offering expenses. The offering is anticipated to close on or about July 16, 2026, with net proceeds allocated for working capital and general corporate purposes.
In conjunction with the warrant exercise, the company will issue new unregistered Series E and Series F warrants to purchase an aggregate of 4.7 million shares of common stock. The Series E warrants will be exercisable immediately upon issuance and will expire five years from the date of issuance, while the Series F warrants will also be exercisable immediately and will expire on the five-year anniversary. H.C. Wainwright & Co. is serving as the exclusive placement agent for the transaction.
This capital injection comes at a critical time as SOBRsafe continues to expand its market presence in the behavioral health, family law, and consumer sectors. The company's transdermal alcohol detection technology, which detects alcohol emitted through the skin in real-time without requiring breath, blood, or urine samples, offers a passive and dignified screening solution. The funds are expected to support ongoing operations, product development, and sales initiatives.
For more details on the offering, the full press release is available at https://nnw.fm/jzJjF. Additional information about SOBRsafe and its technology can be found on the company's website at www.sobrsafe.com.
The successful completion of this warrant exercise demonstrates investor confidence in SOBRsafe's technology and business strategy. By strengthening its balance sheet, the company is better positioned to capitalize on growth opportunities in the alcohol detection monitoring market.
